Reviews/Targeted Therapy Prostate Cancer/PSMA PET staging superior to conventional imaging
Psma · PC-PSMA-02 · v2
When doctors try to find where prostate cancer has spread, the papers here repeatedly show that PSMA PET/CT scans pick up more disease in lymph nodes and bone than older bone scans and CT do, both at first diagnosis and when the cancer comes back after surgery. In a study that checked scan results against tissue removed at surgery, PSMA found far more cancer-containing node areas than the older imaging [12], and another surgical-reference study showed the same pattern at first staging [2]. The scans also found recurrent disease even when blood markers were very low [9][10]. The weaker part of the claim is 'specificity' (correctly ruling disease out): the single paper that measured it found PSMA slightly lower than older imaging, not better [12]. Most of the studies also looked back at past patients rather than following them forward, and several compared PSMA against other scan types rather than the stated bone-scan-plus-CT comparison [15][16][17]. The panel therefore treated the 'more sensitive' part of the claim as well supported and the 'more specific' part as overstated.
Direct comparisons against conventional or morphologic imaging consistently show PSMA PET/CT detecting substantially more nodal and metastatic disease: at primary staging PSMA identified nodal or distant metastases in 56.7% of patients versus 13.3% for CT (p < 0.001), with per-patient nodal accuracy of 90.6% against histopathology [2], and it supported replacing bone scan and CT [1]. In biochemical recurrence, PSMA detected metastatic lymph-node fields in 77.9% versus 26.9% for morphologic imaging against salvage-lymphadenectomy histopathology [12], and its sensitivity was described as superior to standard-of-care imaging at low PSA [10]. High restaging detection efficacy was documented across PSA strata in 251 patients [9]. An anti-PSMA immunoPET agent also showed superior bone-lesion targeting relative to conventional modalities [15]. The contested point: The division is the conjoint 'and specificity' limb: the only corpus paper reporting specificity gives PSMA 97.3% versus morphologic imaging 99.1% [12], i.e. comparable and marginally lower rather than superior. The evidence also leans heavily on retrospective designs with histopathology reference standards only in subsets [2][12].
All 17 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim asserts superior sensitivity AND specificity, but the only included paper reporting specificity ([12]) gives PSMA PET 97.3% vs morphologic imaging 99.1% — i.e. specificity was comparable, marginally lower, not superior. The specificity limb of the claim is not supported by the corpus.
Most included studies ([1],[9],[10]) are retrospective or post-hoc, and complete histopathological reference standards exist only in subsets ([2] n=32; [12] resected fields). 'Detection rate' is not equivalent to measured sensitivity without a full reference standard, so several headline figures overstate diagnostic accuracy.
Where it remains uncertain. The single specificity datapoint shows PSMA at 97.3% versus morphologic imaging 99.1% [12], so the claim's 'and specificity' limb is comparable-to-lower, not superior.
Aleatory
Sample sizes of N = 48–270 in intermediate/high-risk or BCR cohorts leave detection estimates subject to sampling variability [12][10].
Epistemic
Only one paper reports specificity [12], so the specificity limb rests on a single comparison rather than replicated evidence.
Inferential
Headline detection rates [9][10] are treated as diagnostic accuracy despite the absence of a full reference standard.
The load-bearing papers from a corpus of 17, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary-staging evidence favouring PSMA PET/CT over the conventional bone-scan-plus-CT protocol.
“Findings of this study support the replacement of BS and CT by PSMA PET/CT in staging primary PCa.”
Panel auditInternal validity: low · scope of inference: Primary staging of newly diagnosed intermediate/high-risk prostate cancer, not biochemical recurrence.Key limitations: retrospective single centre · small n=64 · no true reference standard · staging not restaging
Prospective, histopathology-validated head-to-head showing PSMA PET/CT detects markedly more disease than CT in primary high-risk staging.
“Compared with BS, PSMA-PET/CT localized unknown skeletal metastases in 15% (9/60) of cases, with no false negative findings.”
Panel auditInternal validity: medium · scope of inference: Primary staging of high-risk prostate cancer candidates for radical prostatectomy, not biochemical recurrence.Key limitations: small n=60 · single cohort · histopathology only in subset · staging not restaging
Documents high restaging detection efficacy across PSA strata, supporting the biochemical-recurrence limb.
“The detection rates were 94.0% (79/84), 90.9% (50/55), 74.5% (35/47), and 61.5% (40/65) for PSA levels of greater than or equal to 2, 1 to less than 2, 0.5 to less than 1, and 0.2 to less than 0.5 ng/mL, respectively.”
Panel auditInternal validity: medium · scope of inference: Detection efficacy of 18F-PSMA-1007 PET/CT for biochemical recurrence after prostatectomy.Key limitations: no conventional comparator · lesions not histologically verified · retrospective
Supporting context that PSMA-targeted PET detects more bone lesions than conventional imaging modalities.
“(89)Zr-J591 imaging demonstrated superior targeting of bone lesions relative to CIMs.”
Panel auditInternal validity: medium · scope of inference: Metastasis detection by a PSMA-targeted antibody immunoPET versus conventional imaging in metastatic castration-resistant prostate cancer.Key limitations: antibody immunoPET not PSMA PET/CT ligand · mCRPC not BCR · no p value for the CIM comparison · soft-tissue accuracy only 60%
4 of 17 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong, reproducible evidence for superior sensitivity/detection vs conventional imaging holds the claim as Likely, while the unsupported specificity limb and reliance on retrospective designs keep it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Specificity head-to-head against conventional imaging. The claim's specificity limb is supported by a single comparison that favours morphologic imaging [12], leaving the conjoint assertion unestablished. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prospective diagnostic-accuracy study reporting both sensitivity and specificity of PSMA PET/CT versus bone scan plus CT against a complete histopathological reference standard.
Open question: Is the specificity of PSMA PET/CT superior to, or at least non-inferior to, bone scan plus CT across staging and restaging? Why it is still open: The only specificity datapoint in the corpus shows PSMA lower than morphologic imaging (97.3% vs 99.1%) [12].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19